Literature DB >> 31038099

Bayesian Evaluation of Three Serological Tests for Detecting Antibodies against Brucella spp. among Humans in the Northwestern Part of Ecuador.

Jorge Ron-Román1,2,3,4, Lenin Ron-Garrido4, Emmanuel Abatih3, Maritza Celi-Erazo4, Laura Vizcaíno-Ordóñez4, Jaime Calva-Pacheco2,1,3,5,4, Pablo González-Andrade3,5,4,2,1, Dirk Berkvens3, Washington Benítez-Ortíz5,3,2,1,4,6, Jef Brandt3, David Fretin7, Claude Saegerman2.   

Abstract

Brucellosis is an important but neglected zoonosis that causes serious economic losses both in livestock and human populations. The aim of the present study was to estimate the true prevalence of brucellosis together with diagnostic sensitivity and specificity of three serological tests in humans of the northwestern part of Ecuador using a Bayesian approach adjusted for the dependencies among the multiple tests to avoid any misinterpretation. In addition, the causal agent responsible for human brucellosis was also identified. Using a total of 3,733 samples collected from humans in this area between 2006 and 2008, the prevalence of human brucellosis and the diagnostic test characteristics of the Rose Bengal fast agglutination test (RBT), Wright's slow agglutination test with ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA) (SAT-EDTA), and indirect ELISA (iELISA) were estimated using a Bayesian approach. The estimated true prevalence of human brucellosis was 1% (credibility interval: 0.4-1.6). The sensitivities of iELISA and RBT were higher than and similar (95.1% and 95.0%, respectively) to those of SAT-EDTA (60.8%). Even though all tests indicated a high specificity (> 99.0%), the specificity of SAT-EDTA was highest (99.9%). The circulating strain in this study area was identified to be Brucella abortus biotype 4 based on culture and microbiological characterization. The RBT and the iELISA are recommended for estimating the true prevalence of human brucellosis and/or for surveillance programs following their high sensitivities and specificities. The proposed strategy supports evidence-based medicine for clinicians and policy-makers to ensure appropriate preventive and control program of brucellosis worldwide.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31038099      PMCID: PMC6553909          DOI: 10.4269/ajtmh.18-0622

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  26 in total

1.  [Incidence, etiology and epidemiology of brucellosis in a rural area of the province of Lleida].

Authors:  J Serra Alvarez; P Godoy García
Journal:  Rev Esp Salud Publica       Date:  2000 Jan-Feb

2.  Effect of diagnostic testing error on intracluster correlation coefficient estimation.

Authors:  A J Branscum; I A Gardner; B A Wagner; P S McInturff; M D Salman
Journal:  Prev Vet Med       Date:  2005-06-10       Impact factor: 2.670

Review 3.  The new global map of human brucellosis.

Authors:  Georgios Pappas; Photini Papadimitriou; Nikolaos Akritidis; Leonidas Christou; Epameinondas V Tsianos
Journal:  Lancet Infect Dis       Date:  2006-02       Impact factor: 25.071

4.  Seroprevalence of brucella antibodies among persons in high-risk occupation in Lebanon.

Authors:  G F Araj; R A Azzam
Journal:  Epidemiol Infect       Date:  1996-10       Impact factor: 2.451

5.  Use of a third class in latent class modelling for the diagnostic evaluation of five infectious salmon anaemia virus detection tests.

Authors:  Charles Caraguel; Henrik Stryhn; Nellie Gagné; Ian Dohoo; Larry Hammell
Journal:  Prev Vet Med       Date:  2011-11-01       Impact factor: 2.670

6.  [Epidemiology and prevention of brucellosis].

Authors:  J Roux
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

7.  First report of orchitis in man caused by Brucella abortus biovar 1 in Ecuador.

Authors:  Jorge Ron-Román; Claude Saegerman; Elizabeth Minda-Aluisa; Washington Benítez-Ortíz; Jef Brandt; Richard Douce
Journal:  Am J Trop Med Hyg       Date:  2012-07-23       Impact factor: 2.345

8.  Comparison of the Brucella Standard Agglutination Test with the ELISA IgG and IgM in patients with Brucella bacteremia.

Authors:  Z A Memish; M Almuneef; M W Mah; L A Qassem; A O Osoba
Journal:  Diagn Microbiol Infect Dis       Date:  2002-10       Impact factor: 2.803

9.  Seroprevalence of brucellosis in Kashmir (India) among patients with pyrexia of unknown origin.

Authors:  S M Kadri; A Rukhsana; M A Laharwal; M Tanvir
Journal:  J Indian Med Assoc       Date:  2000-04

10.  Differentiation of Brucella abortus bv. 1, 2, and 4, Brucella melitensis, Brucella ovis, and Brucella suis bv. 1 by PCR.

Authors:  B J Bricker; S M Halling
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

View more
  1 in total

1.  Performance characteristics and costs of serological tests for brucellosis in a pastoralist community of northern Tanzania.

Authors:  AbdulHamid S Lukambagire; Ângelo J Mendes; Rebecca F Bodenham; John A McGiven; Nestory A Mkenda; Coletha Mathew; Matthew P Rubach; Philoteus Sakasaka; Davis D Shayo; Venance P Maro; Gabriel M Shirima; Kate M Thomas; Christopher J Kasanga; Rudovick R Kazwala; Jo E B Halliday; Blandina T Mmbaga
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.